Greenwich LifeSciences Reports 70-80% Recurrence Reduction Data in 250 Patients
Greenwich LifeSciences had its abstract accepted for presentation at ASCO 2026, showcasing preliminary FLAMINGO-01 non-HLA-A02 arm data. The non-HLA-A02 cohort (250 patients) reported a 70-80% reduction in recurrence rate post-primary immunization series and a 290% rise in DTH reactions to 20.4%.
1. Abstract Acceptance at ASCO 2026
Greenwich LifeSciences announced acceptance of an abstract and poster presentation at the ASCO Annual Meeting from May 28 to June 2, presenting preliminary injection site reaction immune response data from the non-HLA-A*02 open-label arm of FLAMINGO-01.
2. FLAMINGO-01 Non-HLA-A*02 Arm Data
The non-HLA-A*02 cohort of 250 patients reported a preliminary 70-80% reduction in recurrence rate after the six-month primary immunization series and a 290% increase in DTH reactions, rising from 5.2% at baseline to 20.4% at month 4 or 6.
3. Trial Enrollment and Future Presentations
Over 1,300 patients have been screened at approximately 800 per year, with plans to attend ESMO Breast, BIO partnering, and investor conferences; FLAMINGO-01 continues global enrollment across 150 planned sites, randomizing 500 HLA-A*02 patients and treating 250 patients of other HLA types.